Patent ID: 8329920

Claim:
A method of treating Type II diabetes in mammals comprising the step of administering to the mammal in need of such treatment a therapeutically effective amount of a compound of Formula (1C) wherein R 1 is H, (C 1 -C 6 )alkyl, halo-substituted (C 1 -C 3 )alkyl, —S(O) 2 (R 1a ), or C(O)R 1a , where R 1a is (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 3 )alkylamino, or di-(C 1 -C 3 )alkylamino; R 2 is (C 3 -C 6 )cycloalkyl or 5- to 6-membered heterocycle containing one N, O, or S heteroatom, where said cycloalkyl and said heterocycle are optionally substituted with one to two substituents each independently halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, —CF 3 , or cyano; and R 4 is quinolinyl or 5- to 6-membered heteroaryl containing one to two N heteroatoms and optionally one O or S heteroatom, where said heteroaryl and said quinolinyl are optionally substituted with one to two R 4a , where each R 4a is independently (C 1 -C 6 )alkyl optionally substituted with one to three hydroxy, —CF 3 , cyano, (C 1 -C 6 )alkoxy, halo, amino, (C 1 -C 3 )alkylamino, di-(C 1 -C 3 )alkylamino, —CO 2 R 4b , —(C 1 -C 6 )alkylCO 2 R 4b , —C(O)N(R 4b ) 2 , —P(O)(OR 4b ) 2 , —(C 1 -C 6 )alkylP(O)(OR 4b ) 2 , —P(O)(OR 4b )(C 1 -C 3 alkyl), (C 1 -C 3 )alkylsufonyl, —SO 3 H, —NHC(O)R 4c or aryl(C 1 -C 6 )alkyl, where the aryl of said arylalkyl is optionally substituted with (C 1 -C 6 )alkyl, —CF 3 , cyano, (C 1 -C 6 )alkoxy, halo, amino, (C 1 -C 3 )alkylamino, or di-(C 1 -C 3 )alkylamino; R 4b at each occurrence is independently hydrogen, (C 1 -C 6 )alkyl or benzyl; and R 4c at each occurrence is independently CO 2 H or (C 1 -C 6 )alkyl optionally substituted with one to three hydroxy; or a pharmaceutically acceptable salt thereof.